Presentation is loading. Please wait.

Presentation is loading. Please wait.

Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.

Published byKarin Gallagher Modified over 4 years ago

Similar presentations

Presentation on theme: "Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors."— Presentation transcript:

1 Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.
Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. A, whole-cell lysates from the Her2-overexpressing cell lines SKBR3, BT474, and MDA-MB-361 were analyzed for Met, Her2, and actin content by SDS-PAGE followed by Western blot. B, tissue lysates from 10 Her2 (+) human tumors were analyzed for Met, Her2, and actin expression by SDS-PAGE followed by Western blot. David L. Shattuck et al. Cancer Res 2008;68: ©2008 by American Association for Cancer Research

Download ppt "Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors."

Similar presentations

A B C MDA-MB-231 OHT: h FOXM1 PLK CDC25b ERα Tubulin

A B C MDA-MB-231 OHT: h FOXM1 PLK CDC25b ERα Tubulin
EMT correlates with PERK but not IRE1 signaling in primary human tumors. EMT correlates with PERK but not IRE1 signaling in primary human tumors. A, two.

EMT correlates with PERK but not IRE1 signaling in primary human tumors. EMT correlates with PERK but not IRE1 signaling in primary human tumors. A, two.
A549 cells were transfected with the indicated plasmids

A549 cells were transfected with the indicated plasmids
A. D. B. C. - ΔNP63α - β-Actin IMEC - SUM MDA-MB IMEC

A. D. B. C. - ΔNP63α - β-Actin IMEC - SUM MDA-MB IMEC
25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.

25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.
NM-3 induces p21 levels and down-regulation of Cdk2 activity.

NM-3 induces p21 levels and down-regulation of Cdk2 activity.
Increase in beige/brown adipocyte characteristics in the xenografts from additional breast cancer cell lines. Increase in beige/brown adipocyte characteristics.

Increase in beige/brown adipocyte characteristics in the xenografts from additional breast cancer cell lines. Increase in beige/brown adipocyte characteristics.
Overexpression of BTAK/Aurora-A in ovarian carcinoma.

Overexpression of BTAK/Aurora-A in ovarian carcinoma.
Mechanism of piperlongumine induced Sp downregulation.

Mechanism of piperlongumine induced Sp downregulation.
HIPK2 decreases the stability of Notch1-IC through proteasome-dependent degradation. HIPK2 decreases the stability of Notch1-IC through proteasome-dependent.

HIPK2 decreases the stability of Notch1-IC through proteasome-dependent degradation. HIPK2 decreases the stability of Notch1-IC through proteasome-dependent.
Expression changes of specific epigenetic-controlled tumor-related genes by the prenatal/maternal BSp treatment. qRT-PCR and Western blot analysis were.

Expression changes of specific epigenetic-controlled tumor-related genes by the prenatal/maternal BSp treatment. qRT-PCR and Western blot analysis were.
Knocking down Wnt3 increases the cells' response to trastuzumab and reduces cells' invasiveness. Knocking down Wnt3 increases the cells' response to trastuzumab.

Knocking down Wnt3 increases the cells' response to trastuzumab and reduces cells' invasiveness. Knocking down Wnt3 increases the cells' response to trastuzumab.
PTK6 downregulation suppresses SNAIL and increases E-cadherin expression. PTK6 downregulation suppresses SNAIL and increases E-cadherin expression. A,

PTK6 downregulation suppresses SNAIL and increases E-cadherin expression. PTK6 downregulation suppresses SNAIL and increases E-cadherin expression. A,
The p53 pathway is involved in the inhibition of cell proliferation observed in 15-LOX-1-overexpressing cells. The p53 pathway is involved in the inhibition.

The p53 pathway is involved in the inhibition of cell proliferation observed in 15-LOX-1-overexpressing cells. The p53 pathway is involved in the inhibition.
co-IP of LEDGF/p75 and MeCP2.

co-IP of LEDGF/p75 and MeCP2.
TFAP2A is highly expressed in nasopharyngeal carcinoma cells and tumor tissues. TFAP2A is highly expressed in nasopharyngeal carcinoma cells and tumor.

TFAP2A is highly expressed in nasopharyngeal carcinoma cells and tumor tissues. TFAP2A is highly expressed in nasopharyngeal carcinoma cells and tumor.
Variation in dUTPase expression in cell lines.

Variation in dUTPase expression in cell lines.
CDCP1 is required for invadopodia formation and ECM degradation by human breast cancer cells. CDCP1 is required for invadopodia formation and ECM degradation.

CDCP1 is required for invadopodia formation and ECM degradation by human breast cancer cells. CDCP1 is required for invadopodia formation and ECM degradation.
The role of p53 in H2O2-mediated cell death of hOGG1-deficient H1299 lung carcinoma p53 null cells. The role of p53 in H2O2-mediated cell death of hOGG1-deficient.

The role of p53 in H2O2-mediated cell death of hOGG1-deficient H1299 lung carcinoma p53 null cells. The role of p53 in H2O2-mediated cell death of hOGG1-deficient.
Subcutaneous tumor growth was significantly increased in Ogt-Tg/+ mice

Subcutaneous tumor growth was significantly increased in Ogt-Tg/+ mice

Similar presentations

Ads by Google